These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19708032)

  • 61. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.
    Sasaki K; Kantarjian H; Wierda W; Ravandi-Kashani F; Jorgensen J; Wang SA; Khoury J; Daver N; Burger J; Di Nardo CD; Jain N; Short NJ; Estrov Md Z; Konopleva Md PhD M; Ohanian DO M; Garcia-Manero G; Kadia T; Alvarado-Valero Y; Yilmaz M; Pierce S; Garris R; Ingram A; Cortes J; OʼBrien S; Jabbour E
    Am J Hematol; 2020 Jul; 95(7):734-739. PubMed ID: 32170867
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
    Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
    Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.
    Hunault-Berger M; Leguay T; Thomas X; Legrand O; Huguet F; Bonmati C; Escoffre-Barbe M; Legros L; Turlure P; Chevallier P; Larosa F; Garban F; Reman O; Rousselot P; Dhédin N; Delannoy A; Lafage-Pochitaloff M; Béné MC; Ifrah N; Dombret H;
    Haematologica; 2011 Feb; 96(2):245-52. PubMed ID: 20971822
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature.
    Pathak P; Hess R; Weiss MA
    Ther Adv Hematol; 2014 Feb; 5(1):18-24. PubMed ID: 24490021
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
    Verma D; O'Brien S; Thomas D; Faderl S; Koller C; Pierce S; Kebriaei P; Garcia-Manero G; Cortes J; Kantarjian H; Ravandi F
    Cancer; 2009 Jan; 115(1):101-6. PubMed ID: 19090005
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
    Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
    Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.
    Carraway HE; Sawalha Y; Gojo I; Lee MJ; Lee S; Tomita Y; Yuno A; Greer J; Smith BD; Pratz KW; Levis MJ; Gore SD; Ghosh N; Dezern A; Blackford AL; Baer MR; Gore L; Piekarz R; Trepel JB; Karp JE
    Leuk Res; 2021 Nov; 110():106707. PubMed ID: 34563945
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
    Faderl S; Balakrishnan K; Thomas DA; Ravandi F; Borthakur G; Burger J; Ferrajoli A; Cortes J; O'Brien S; Kadia T; Feliu J; Plunkett W; Gandhi V; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):231-8. PubMed ID: 24440659
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
    Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
    Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
    Jo JC; Baek JH; Lee JH; Joo YD; Bae SH; Lee JL; Lee JH; Kim DY; Lee WS; Ryoo HM; Choi Y; Kim H; Lee KH;
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):159-66. PubMed ID: 26956432
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
    Chari A; Htut M; Zonder JA; Fay JW; Jakubowiak AJ; Levy JB; Lau K; Burt SM; Tunquist BJ; Hilder BW; Rush SA; Walker DH; Ptaszynski M; Kaufman JL
    Cancer; 2016 Nov; 122(21):3327-3335. PubMed ID: 27433944
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
    Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
    Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22
    Pennesi E; Brivio E; Ammerlaan ACJ; Jiang Y; Van der Velden VHJ; Beverloo HB; Sleight B; Locatelli F; Brethon B; Rossig C; Engstler G; Nilsson A; Bruno B; Petit A; Bielorai B; Rizzari C; Rialland F; Rubio-San-Simón A; Sirvent FJB; Diaz-de-Heredia C; Rives S; Zwaan CM
    Haematologica; 2024 Oct; 109(10):3157-3166. PubMed ID: 38186333
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
    Higashigawa M; Hori H; Hirayama M; Kawasaki H; Ido M; Azuma E; Sakurai M
    Leuk Res; 1997 Sep; 21(9):811-5. PubMed ID: 9393595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.